Top PharmaCyte Insiders Quietly Boost Their Holdings in a Big Way
I'm PortAI, I can summarize articles.
PharmaCyte Biotech (PMCB) experienced significant insider buying on January 7, 2026, with CEO Joshua Silverman purchasing 100,000 shares for $80,000 and Director Jonathan Schechter acquiring 60,000 shares for $48,000, totaling 160,000 shares and $128,000. The company also announced a delay in filing its Form 10-Q for the period ending October 31, 2025, citing the need for more time to ensure accurate financial disclosures. Despite this, no significant changes in financial results are expected, and the stock currently has a 'Sell' technical sentiment signal with a market cap of $7.72M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments